Diagnosis of Bone Marrow Involvement in Pediatric Lymphoma Patients: FDG PET/CT Versus Bone Marrow Biopsy

  • Gang Cheng
Part of the Pediatric Cancer book series (PECA, volume 4)


Bone marrow infiltration (BMI) is common in patients with Hodgkin’s disease (HD) and non Hodgkin’s lymphoma (NHL), often indicates poor prognosis. Accurate assessment of BMI is critical for staging and selection of proper therapeutic options in lymphoma patients. Up to now, bone marrow biopsy (BMB) is an integral part of initial work-up in these patients, although it has a high false negative rate. In recent years, FDG PET/CT has established as a highly accurate imaging tool in the assessment of Hodgkin’s disease and non-Hodgkin’s lymphoma. Multiple studies have found that FDG PET/CT in the initial diagnosis work-up detects more bone marrow involvement in lymphoma patients thus are more sensitive and more accurate than bilateral bone marrow biopsy performed at the iliac crest. At the same time, it has been shown that BMB performed based on findings of FDG PET/CT significantly decreased false negative findings and improved accuracy of BMB. In this review, we discuss the value of FDG PET/CT in identifying BMI and in guiding BMB in the initial evaluation of pediatric lymphoma patients.


Bone Marrow Biopsy Bone Marrow Involvement Bone Marrow Lesion Bone Marrow Infiltration High False Negative Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Allen-Auerbach M, de Vos S, Czernin J (2008) The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin N Am 46:199–211PubMedCrossRefGoogle Scholar
  2. Campbell JK, Matthews JP, Seymour JF, Wolf MM, Juneja SK, Australasian Leukaemia Lymphoma G (2003) Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Ann Oncol 14:273–276PubMedCrossRefGoogle Scholar
  3. Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging 38:1469–1476PubMedCrossRefGoogle Scholar
  4. Cheng G, Alavi A, Zhuang H (2012) Clinical application of FDG PET/CT in pediatric lymphoma patients. PET Clin 7:47–56CrossRefGoogle Scholar
  5. Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, Paquet N, Foidart J, Rigo P, Hustinx R (2005) 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 32:31–38PubMedCrossRefGoogle Scholar
  6. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A (2006) Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun 27:11–15PubMedCrossRefGoogle Scholar
  7. Gemmel F, Eshuis SA, van Vollenhoven F, Gemmel P (2012) Osteoblastic healing response: discordant PET/CT findings. Eur J Nucl Med Mol Imaging 39:184–185PubMedCrossRefGoogle Scholar
  8. Juneja SK, Wolf MM, Cooper IA (1990) Value of bilateral bone marrow biopsy specimens in non-Hodgkin’s lymphoma. J Clin Pathol 43:630–632PubMedCrossRefGoogle Scholar
  9. Kabickova E, Sumerauer D, Cumlivska E, Drahokoupilova E, Nekolna M, Chanova M, Hladikova M, Kodet R, Belohlavek O (2006) Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur J Nucl Med Mol Imaging 33:1025–1031PubMedCrossRefGoogle Scholar
  10. Klaeser B, Wiskirchen J, Wartenberg J, Weitzel T, Schmid RA, Mueller MD, Krause T (2010) PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging 37:2027–2036PubMedCrossRefGoogle Scholar
  11. Levis A, Pietrasanta D, Godio L, Vitolo U, Ciravegna G, Di Vito F, Gavarotti P, Guglielmelli T, Orsucci L, Raviolo E et al (2004) A large-scale study of bone marrow involvement in patients with Hodgkin’s lymphoma. Clin Lymphoma 5:50–55PubMedCrossRefGoogle Scholar
  12. Menon NC, Buchanan JG (1979) Bilateral trephine bone marrow biopsies in Hodgkin’s and non-Hodgkin’s lymphoma. Pathology 11:53–57PubMedCrossRefGoogle Scholar
  13. Moid F, DePalma L (2005) Comparison of relative value of bone marrow aspirates and bone marrow trephine biopsies in the diagnosis of solid tumor metastasis and Hodgkin lymphoma: institutional experience and literature review. Arch Pathol Lab Med 129:497–501PubMedGoogle Scholar
  14. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN (1998) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609PubMedGoogle Scholar
  15. Moulin-Romsee G, Hindié E, Cuenca X, Brice P, Decaudin D, Bénamor M, Brière J, Anitei M, Filmont J-E, Sibon D et al (2010) 18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37:1095–1105PubMedCrossRefGoogle Scholar
  16. Muslimani AA, Farag HL, Francis S, Spiro TP, Chaudhry AA, Chan VC, Taylor HC, Daw HA (2008) The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol 31:409–412PubMedCrossRefGoogle Scholar
  17. Pakos EE, Fotopoulos AD, Ioannidis JPA (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46:958–963PubMedGoogle Scholar
  18. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G (2008a) FDG-PET in the detection of bone marrow disease in Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 52:9–16PubMedGoogle Scholar
  19. Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, Vitolo U, Mancini M, Bisi G, Gallo E (2008b) Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med 113:578–590PubMedCrossRefGoogle Scholar
  20. Pelosi E, Penna D, Douroukas A, Bello M, Amati A, Arena V, Passera R, Bisi G (2011) Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging 55:469–475PubMedGoogle Scholar
  21. Purz S, Mauz-Korholz C, Korholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O et al (2011) [18F]Fluorodeoxyglucose Positron Emission Tomography for detection of bone marrow involvement in children and adolescents With Hodgkin’s lymphoma. J Clin Oncol 29:3523–3528PubMedCrossRefGoogle Scholar
  22. Quereux G, Frot AS, Brocard A, Leux C, Renaut J-J, Dreno B (2009) Routine bone marrow biopsy in the initial evaluation of primary cutaneous B-cell lymphoma does not appear justified. Eur J Dermatol 19:216–220PubMedGoogle Scholar
  23. Ribrag V, Vanel D, Leboulleux S, Lumbroso J, Couanet D, Bonniaud G, Auperin A, Masson F, Bosq J, Edeline V et al (2008) Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol 66:325–331PubMedCrossRefGoogle Scholar
  24. Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau A, Le Gouill S, Berthou C, Moreau P, Kraeber-Bodere F (2009) Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 36:1813–1821PubMedCrossRefGoogle Scholar
  25. Schaefer NG, Strobel K, Taverna C, Hany TF (2007a) Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 34:60–67PubMedCrossRefGoogle Scholar
  26. Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF (2007b) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy–is biopsy of FDG-avid lesions still needed? Radiology 244:257–262PubMedCrossRefGoogle Scholar
  27. Subramanian R, Basu D, Badhe B, Dutta TK (2007) Role of bone marrow trephine biopsy in the diagnosis of marrow involvement in Hodgkin’s disease. Indian J Pathol Microbiol 50:640–643PubMedGoogle Scholar
  28. Tatli S, Gerbaudo VH, Mamede M, Tuncali K, Shyn PB, Silverman SG (2010) Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology 256:305–311PubMedCrossRefGoogle Scholar
  29. Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, Arber DA (2002) Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 94:1522–1531PubMedCrossRefGoogle Scholar
  30. Weiss C, Nour S, Lewin J (2008) MR-guided biopsy: a review of current techniques and applications. J Magn Reson Imaging 27:311–325PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Philadelphia VA Medical Center and Hospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations